Kamada Discontinues Phase 3 Trial, Still Eyes 2026 Growth
Ticker: KMDA · Form: 6-K · Filed: Dec 8, 2025 · CIK: 1567529
| Field | Detail |
|---|---|
| Company | Kamada Ltd (KMDA) |
| Form Type | 6-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | mixed |
Sentiment: mixed
Topics: clinical-trial-discontinuation, guidance, biotech
TL;DR
Kamada scrapped its inhaled AAT Phase 3 trial but says 2025 guidance is intact and 2026 will see double-digit growth.
AI Summary
Kamada Ltd. announced on December 8, 2025, the discontinuation of its Phase 3 clinical trial for inhaled Alpha-1 Antitrypsin (AAT). Despite this setback, the company reiterated its 2025 full-year financial guidance and projects double-digit growth in revenues and profitability for 2026.
Why It Matters
The discontinuation of a Phase 3 trial can impact future revenue streams and investor confidence, though the company's reiteration of guidance suggests resilience.
Risk Assessment
Risk Level: medium — Discontinuing a Phase 3 trial is a significant event that introduces uncertainty regarding future product development and revenue, although the company's forward-looking guidance mitigates some risk.
Key Numbers
- Double-digit — Projected Growth 2026 (Kamada projects double-digit growth in revenues and profitability for the upcoming year.)
Key Players & Entities
- Kamada Ltd. (company) — The company filing the report and announcing the trial discontinuation.
- Alpha-1 Antitrypsin (AAT) (drug) — The therapeutic protein being tested in the discontinued Phase 3 clinical trial.
- December 8, 2025 (date) — The date of the announcement regarding the trial discontinuation and guidance.
FAQ
What was the specific reason for discontinuing the Phase 3 inhaled AAT clinical trial?
The filing does not specify the exact reason for the discontinuation of the Phase 3 inhaled AAT clinical trial, only that it has been discontinued.
Which specific Form S-8 Registration Statements is this 6-K being incorporated into?
This Form 6-K is being incorporated by reference into Kamada Ltd.'s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, and 333-265866.
What is Kamada Ltd.'s projected financial performance for 2026?
Kamada Ltd. projects double-digit growth in revenues and profitability for the full year 2026.
Does Kamada Ltd. expect to meet its 2025 full-year financial guidance?
Yes, the company reiterates its 2025 full-year guidance despite the trial discontinuation.
What is Kamada Ltd.'s principal executive office address?
Kamada Ltd.'s principal executive offices are located at 2 Holzman Street Science Park, P.O. Box 4081, Rehovot 7670402, Israel.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2025-12-08 07:00:07
Filing Documents
- ea0268786-6k_kamada.htm (6-K) — 13KB
- ea026878601ex99-1_kamada.htm (EX-99.1) — 16KB
- 0001213900-25-118940.txt ( ) — 30KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of December 2025 Commission File Number 001-35948 Kamada Ltd. (Translation of registrant’s name into English) 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720 , 333-207933 , 333-215983 , 333-222891 , 333-233267 and 333-265866 . 1 The following exhibit is attached: 99.1 Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 8, 2025 KAMADA LTD. By: /s/ Nir Livneh Nir Livneh Vice President General Counsel and Corporate Secretary 3 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 4